𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

✍ Scribed by C. Kollmannsberger; J. T. Hartmann; L. Kanz; C. Bokemeyer

Publisher
Springer-Verlag
Year
1998
Tongue
English
Weight
296 KB
Volume
124
Category
Article
ISSN
1432-1335

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Results of intensive chemotherapy in 998
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome
✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Elderly patients (age β‰₯ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s

P53 is the strongest predictor of surviv
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support
✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 129 KB πŸ‘ 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen